Search

Your search keyword '"Soldani, Fabio"' showing total 37 results
Start Over Author "Soldani, Fabio"
37 results on '"Soldani, Fabio"'

1. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

Author

Paul, Mical, Carratala, Jordi, Oriol, Isabel, Rodríguez-Álvarez, Regino José, Cordero, Elisa, Lepe, José Antonio, de Lucas, Esperanza Merino, Muñoz, Patricia, Fortún, Jesús, Coussement, Julien, Dewispelaere, Laurent, Eriksson, Britt Marie, van Delden, Christian, Manuel, Oriol, Clemente, Wanessa T., Strabelli, Tania Mara Varejão, Pilmis, Benoit, Roilides, Emmanuel, Ranganathan N, Iyer, Grossi, Paolo A., Soldani, Fabio, Rizzi, Marco, Tan, Ban Hock, Lowman, Warren, Gunseren, Filiz, Arslan, Hande, Tufan, Zeliha Koçak, Kazak, Esra, David, Miruna D., Steinke, Seema Mehta, Ostrander, Darin, Avery, Robin, Lease, Erika D., Pérez-Nadales, Elena, Fernández-Ruiz, Mario, Natera, Alejandra M., Gutiérrez-Gutiérrez, Belén, Mularoni, Alessandra, Russelli, Giovanna, Pierrotti, Ligia Camera, Pinheiro Freire, Maristela, Falcone, Marco, Tiseo, Giusy, Tumbarello, Mario, Raffaelli, Francesca, Abdala, Edson, Bodro, Marta, Gervasi, Elena, Fariñas, María Carmen, Seminari, Elena M., Castón, Juan José, Marín-Sanz, Juan Antonio, Gálvez-Soto, Víctor, Rana, Meenakshi M., Loeches, Belén, Martín-Dávila, Pilar, Pascual, Álvaro, Rodríguez-Baño, Jesús, Aguado, José María, Martínez-Martínez, Luis, and Torre-Cisneros, Julián

Published
2023
Full Text
View/download PDF

2. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

Author

Pérez-Nadales, Elena, Gutiérrez-Gutiérrez, Belén, Natera, Alejandra M., Abdala, Edson, Reina Magalhães, Maira, Mularoni, Alessandra, Monaco, Francesco, Camera Pierrotti, Ligia, Pinheiro Freire, Maristela, Iyer, Ranganathan N., Mehta Steinke, Seema, Grazia Calvi, Elisa, Tumbarello, Mario, Falcone, Marco, Fernández-Ruiz, Mario, Costa-Mateo, José María, Rana, Meenakshi M., Mara Varejão Strabelli, Tania, Paul, Mical, Carmen Fariñas, María, Clemente, Wanessa Trindade, Roilides, Emmanuel, Muñoz, Patricia, Dewispelaere, Laurent, Loeches, Belén, Lowman, Warren, Hock Tan, Ban, Escudero-Sánchez, Rosa, Bodro, Marta, Antonio Grossi, Paolo, Soldani, Fabio, Gunseren, Filiz, Nestorova, Nina, Pascual, Álvaro, Martínez-Martínez, Luis, Aguado, JoséMaría, Rodríguez-Baño, Jesús, and Torre-Cisneros, Julián

Published
2020
Full Text
View/download PDF

4. Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting

Author

Puro, Vincenzo, Cicalini, Stefania, De Carli, Gabriella, Soldani, Fabio, Antunes, Francisco, Balslev, Ulla, Begovac, Josip, Bernasconi, Enos, Boaventura, José L., Martí, Magda Campins, Civljak, Rok, Evans, Barry, Francioli, Patrick, Genasi, Fiona, Larsen, Christine, Lot, Florence, Lunding, Suzanne, Marcus, Ulrich, Pereira, Alvaro A., Thomas, Tania, Schonwald, Slavko, and Ippolito, Giuseppe

Published
2004

5. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

Author

Pérez-Nadales, Elena, primary, Fernández-Ruiz, Mario, additional, Natera, Alejandra M., additional, Gutiérrez-Gutiérrez, Belén, additional, Mularoni, Alessandra, additional, Russelli, Giovanna, additional, Camera Pierrotti, Ligia, additional, Pinheiro Freire, Maristela, additional, Falcone, Marco, additional, Tiseo, Giusy, additional, Tumbarello, Mario, additional, Raffaelli, Francesca, additional, Abdala, Edson, additional, Bodro, Marta, additional, Gervasi, Elena, additional, Fariñas, María Carmen, additional, Seminari, Elena M., additional, Castón, Juan José, additional, Marín-Sanz, Juan Antonio, additional, Gálvez-Soto, Víctor, additional, Rana, Meenakshi M., additional, Loeches, Belén, additional, Martín-Dávila, Pilar, additional, Pascual, Álvaro, additional, Rodríguez-Baño, Jesús, additional, Aguado, José María, additional, Martínez-Martínez, Luis, additional, Torre-Cisneros, Julián, additional, Paul, Mical, additional, Carratala, Jordi, additional, Oriol, Isabel, additional, Rodríguez-Álvarez, Regino José, additional, Cordero, Elisa, additional, Lepe, José Antonio, additional, de Lucas, Esperanza Merino, additional, Muñoz, Patricia, additional, Fortún, Jesús, additional, Coussement, Julien, additional, Dewispelaere, Laurent, additional, Eriksson, Britt Marie, additional, van Delden, Christian, additional, Manuel, Oriol, additional, Clemente, Wanessa T., additional, Strabelli, Tania Mara Varejão, additional, Pilmis, Benoit, additional, Roilides, Emmanuel, additional, Ranganathan N, Iyer, additional, Grossi, Paolo A., additional, Soldani, Fabio, additional, Rizzi, Marco, additional, Tan, Ban Hock, additional, Lowman, Warren, additional, Gunseren, Filiz, additional, Arslan, Hande, additional, Tufan, Zeliha Koçak, additional, Kazak, Esra, additional, David, Miruna D., additional, Steinke, Seema Mehta, additional, Ostrander, Darin, additional, Avery, Robin, additional, and Lease, Erika D., additional

Published
2023
Full Text
View/download PDF

7. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients

Author

Gutierrez-Gutierrez, Belen, Perez-Nadales, Elena, Perez-Galera, Salvador, Fernandez-Ruiz, Mario, Carratala, Jordi, Oriol, Isabel, Cordero, Elisa, Antonio Lepe, Jose, Tan, Ban Hock, Corbella, Laura, Paul, Mical, Natera, Alejandra M., David, Miruna D., Montejo, Miguel, Iyer, Ranganathan N., Pierrotti, Ligia Camera, Merino, Esperanza, Steinke, Seema Mehta, Rana, Meenakshi M., Munoz, Patricia, Mularoni, Alessandra, van Delden, Christian, Grossi, Paolo Antonio, Seminari, Elena Maria, Gunseren, Filiz, Lease, Erika D., Roilides, Emmanuel, Fortun, Jesus, Arslan, Hande, Coussement, Julien, Tufan, Zeliha Kocak, Pilmis, Benoit, Rizzi, Marco, Loeches, Belen, Eriksson, Britt-Marie, Abdala, Edson, Soldani, Fabio, Lowman, Warren, Clemente, Wanessa Trindade, Bodro, Marta, Carmen Farinas, Maria, Kazak, Esra, Martinez-Martinez, Luis, Maria Aguado, Jose, Torre-Cisneros, Julian, Pascual, Alvaro, Rodriguez-Bano, Jesus, Gutierrez-Gutierrez, Belen, Perez-Nadales, Elena, Perez-Galera, Salvador, Fernandez-Ruiz, Mario, Carratala, Jordi, Oriol, Isabel, Cordero, Elisa, Antonio Lepe, Jose, Tan, Ban Hock, Corbella, Laura, Paul, Mical, Natera, Alejandra M., David, Miruna D., Montejo, Miguel, Iyer, Ranganathan N., Pierrotti, Ligia Camera, Merino, Esperanza, Steinke, Seema Mehta, Rana, Meenakshi M., Munoz, Patricia, Mularoni, Alessandra, van Delden, Christian, Grossi, Paolo Antonio, Seminari, Elena Maria, Gunseren, Filiz, Lease, Erika D., Roilides, Emmanuel, Fortun, Jesus, Arslan, Hande, Coussement, Julien, Tufan, Zeliha Kocak, Pilmis, Benoit, Rizzi, Marco, Loeches, Belen, Eriksson, Britt-Marie, Abdala, Edson, Soldani, Fabio, Lowman, Warren, Clemente, Wanessa Trindade, Bodro, Marta, Carmen Farinas, Maria, Kazak, Esra, Martinez-Martinez, Luis, Maria Aguado, Jose, Torre-Cisneros, Julian, Pascual, Alvaro, and Rodriguez-Bano, Jesus

Abstract

There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.

Published
2021
Full Text
View/download PDF

8. Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)

Author

Pierrotti, Ligia C., Perez-Nadales, Elena, Fernandez-Ruiz, Mario, Gutierrez-Gutierrez, Belen, Hock Tan, Ban, Carratala, Jordi, Oriol, Isabel, Paul, Mical, Cohen-Sinai, Noa, Lopez-Medrano, Francisco, San-Juan, Rafael, Montejo, Miguel, Freire, Maristela P., Cordero, Elisa, David, Miruna D., Merino, Esperanza, Mehta Steinke, Seema, Grossi, Paolo A., Cano, Angela, Seminari, Elena M., Valerio, Maricela, Gunseren, Filiz, Rana, Meenakshi, Mularoni, Alessandra, Martin-Davila, Pilar, van Delden, Christian, Hamiyet Demirkaya, Melike, Kocak Tufan, Zeliha, Loeches, Belen, Iyer, Ranganathan N., Soldani, Fabio, Eriksson, Britt-Marie, Pilmis, Benoit, Rizzi, Marco, Coussement, Julien, Clemente, Wanessa T., Roilides, Emmanuel, Pascual, Alvaro, Martinez-Martinez, Luis, Rodriguez-Bano, Jesus, Torre-Cisneros, Julian, Maria Aguado, Jose, Pierrotti, Ligia C., Perez-Nadales, Elena, Fernandez-Ruiz, Mario, Gutierrez-Gutierrez, Belen, Hock Tan, Ban, Carratala, Jordi, Oriol, Isabel, Paul, Mical, Cohen-Sinai, Noa, Lopez-Medrano, Francisco, San-Juan, Rafael, Montejo, Miguel, Freire, Maristela P., Cordero, Elisa, David, Miruna D., Merino, Esperanza, Mehta Steinke, Seema, Grossi, Paolo A., Cano, Angela, Seminari, Elena M., Valerio, Maricela, Gunseren, Filiz, Rana, Meenakshi, Mularoni, Alessandra, Martin-Davila, Pilar, van Delden, Christian, Hamiyet Demirkaya, Melike, Kocak Tufan, Zeliha, Loeches, Belen, Iyer, Ranganathan N., Soldani, Fabio, Eriksson, Britt-Marie, Pilmis, Benoit, Rizzi, Marco, Coussement, Julien, Clemente, Wanessa T., Roilides, Emmanuel, Pascual, Alvaro, Martinez-Martinez, Luis, Rodriguez-Bano, Jesus, Torre-Cisneros, Julian, and Maria Aguado, Jose

Abstract

Background Whether active therapy with beta-lactam/beta-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear. Methods We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively. Results Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count <= 500 cells/mu L at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. Conclusions Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).

Published
2021
Full Text
View/download PDF

9. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients

Author

Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Red Española de Investigación en Patología Infecciosa, European Commission, Sociedad Andaluza de Trasplante de Órganos y Tejidos, Ministerio de Ciencia e Innovación (España), Gutiérrez-Gutiérrez, Belén, Pérez-Nadales, Elena, Pérez-Galera, Salvador, Fernández-Ruiz, Mario, Carratalà, Jordi, Oriol, Isabel, Cordero-Matía, Elisa, Lepe, José A., Tan, Ban Hock, Corbella, Laura, Paul, Mical, Natera, Alejandra M., David, Miruna D., Montejo, Miguel, Iyer, Ranganathan N., Camera Pierrotti, Ligia, Merino, Esperanza, Steinke, Seema Mehta, Rana, Meenakshi M., Muñoz, Patricia, Mularoni, Alessandra, van Delden, Christian, Grossi, Paolo Antonio, Seminari, Elena María, Gunseren, Filiz, Lease, Erika D., Fortún, Emmanuel, Roilides, Jesús, Arslan, Hande, Coussement, Julien, Tufan, Zeliha Koçak, Pilmis, Benoît, Rizzi, Marco, Loeches, Belén, Eriksson, Britt Marie, Abdala, Edson, Soldani, Fabio, Lowman, Warren, Clemente, Wanessa T., Bodro, Marta, Fariñas, María del Carmen, Kazak, Esra, Martínez-Martínez, Luis, Aguado, José María, Torre-Cisneros, Julián, Pascual, Álvaro, Rodríguez-Baño, Jesús, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Red Española de Investigación en Patología Infecciosa, European Commission, Sociedad Andaluza de Trasplante de Órganos y Tejidos, Ministerio de Ciencia e Innovación (España), Gutiérrez-Gutiérrez, Belén, Pérez-Nadales, Elena, Pérez-Galera, Salvador, Fernández-Ruiz, Mario, Carratalà, Jordi, Oriol, Isabel, Cordero-Matía, Elisa, Lepe, José A., Tan, Ban Hock, Corbella, Laura, Paul, Mical, Natera, Alejandra M., David, Miruna D., Montejo, Miguel, Iyer, Ranganathan N., Camera Pierrotti, Ligia, Merino, Esperanza, Steinke, Seema Mehta, Rana, Meenakshi M., Muñoz, Patricia, Mularoni, Alessandra, van Delden, Christian, Grossi, Paolo Antonio, Seminari, Elena María, Gunseren, Filiz, Lease, Erika D., Fortún, Emmanuel, Roilides, Jesús, Arslan, Hande, Coussement, Julien, Tufan, Zeliha Koçak, Pilmis, Benoît, Rizzi, Marco, Loeches, Belén, Eriksson, Britt Marie, Abdala, Edson, Soldani, Fabio, Lowman, Warren, Clemente, Wanessa T., Bodro, Marta, Fariñas, María del Carmen, Kazak, Esra, Martínez-Martínez, Luis, Aguado, José María, Torre-Cisneros, Julián, Pascual, Álvaro, and Rodríguez-Baño, Jesús

Abstract

There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.

Published
2021

10. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

Author

European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, Pérez-Nadales, Elena, Gutiérrez-Gutiérrez, Belén, Natera, Alejandra M., Abdala, Edson, Reina Magalhães, Maira, Mularoni, Alessandra, Monaco, Francesco, Camera Pierrotti, Ligia, Pinheiro Freire, Maristela, Iyer, Ranganathan N., Mehta Steinke, Seema, Grazia Calvi, Elisa, Tumbarello, Mario, Falcone, Marco, Fernández-Ruiz, Mario, Costa-Mateo, Jose M., Rana, Meenakshi M., Mara Varejao Strabelli, Tania, Paul, Mical, Fariñas, María del Carmen, Trindade Clemente, Wanessa, Roilides, Emmanuel, Muñoz García, Patricia, Dewispelaere, Laurent, Loeches, Belén, Lowman, Warren, Hock Tan, Ban, Escudero-Sánchez, Rosa, Bodro, Marta, Grossi, Paolo Antonio, Soldani, Fabio, Gunseren, Filiz, Nestorova, Nina, Pascual, Álvaro, Martínez-Martínez, Luis, Aguado, José María, Torre-Cisneros, Julián, European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, Pérez-Nadales, Elena, Gutiérrez-Gutiérrez, Belén, Natera, Alejandra M., Abdala, Edson, Reina Magalhães, Maira, Mularoni, Alessandra, Monaco, Francesco, Camera Pierrotti, Ligia, Pinheiro Freire, Maristela, Iyer, Ranganathan N., Mehta Steinke, Seema, Grazia Calvi, Elisa, Tumbarello, Mario, Falcone, Marco, Fernández-Ruiz, Mario, Costa-Mateo, Jose M., Rana, Meenakshi M., Mara Varejao Strabelli, Tania, Paul, Mical, Fariñas, María del Carmen, Trindade Clemente, Wanessa, Roilides, Emmanuel, Muñoz García, Patricia, Dewispelaere, Laurent, Loeches, Belén, Lowman, Warren, Hock Tan, Ban, Escudero-Sánchez, Rosa, Bodro, Marta, Grossi, Paolo Antonio, Soldani, Fabio, Gunseren, Filiz, Nestorova, Nina, Pascual, Álvaro, Martínez-Martínez, Luis, Aguado, José María, and Torre-Cisneros, Julián

Abstract

Treatment of carbapenemase‐producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid organ transplant recipients with carbapenemase‐producing Enterobacterales bloodstream infections. A multinational, retrospective (2004‐2016) cohort study (INCREMENT‐SOT, ClinicalTrials.gov NCT02852902) was performed. The main outcome variable was 30‐day all‐cause mortality. The INCREMENT‐SOT‐CPE score was developed using logistic regression. The global cohort included 216 patients. The final logistic regression model included the following variables: INCREMENT‐CPE mortality score ≥8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between INCREMENT‐CPE score ≥8 and CMV disease (minus 7 points). This score showed an area under the receiver operating characteristic curve of 0.82 (95% confidence interval [CI] 0.76‐0.88) and classified patients into 3 strata: 0‐7 (low mortality), 8‐11 (high mortality), and 12‐17 (very‐high mortality). We performed a stratified analysis of the effect of monotherapy vs combination therapy among 165 patients who received appropriate therapy. Monotherapy was associated with higher mortality only in the very‐high (adjusted hazard ratio [HR] 2.82, 95% CI 1.13‐7.06, P = .03) and high (HR 9.93, 95% CI 2.08‐47.40, P = .004) mortality risk strata. A score‐based algorithm is provided for therapy guidance.

Published
2020

14. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study

Author

Bozzetti, Silvia, primary, Rossini, Fabio, additional, Ferrari, Sergio, additional, Delogu, Rachele, additional, Cantalupo, Gaetano, additional, Marchioretto, Fabio, additional, Zanette, Giampietro, additional, Zanoni, Tiziano, additional, Turatti, Marco, additional, Vitale, Giuseppina, additional, Cadaldini, Morena, additional, Rossi, Francesca, additional, Di Tizio, Luca, additional, Zuco, Carmela, additional, Maniscalco, Giorgia Teresa, additional, Soldani, Fabio, additional, Monaco, Salvatore, additional, Trinka, Eugen, additional, Hoeftberger, Romana, additional, and Mariotto, Sara, additional

Published
2020
Full Text
View/download PDF

15. Outbreak of Saprochaete clavata Sepsis in Hematology Patients: Combined Use of MALDI-TOF and Sequencing Strategy to Identify and Correlate the Episodes

Author

Lo Cascio, Giuliana, primary, Vincenzi, Marcello, additional, Soldani, Fabio, additional, De Carolis, Elena, additional, Maccacaro, Laura, additional, Sorrentino, Annarita, additional, Nadali, Gianpaolo, additional, Cesaro, Simone, additional, Sommavilla, Michele, additional, Niero, Valentina, additional, Naso, Laura, additional, Grancini, Anna, additional, Azzini, Anna Maria, additional, Sanguinetti, Maurizio, additional, Tacconelli, E., additional, and Cornaglia, Giuseppe, additional

Published
2020
Full Text
View/download PDF

17. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

Author

Pérez-Nadales, Elena, Gutiérrez-Gutiérrez, Belén, Natera, Alejandra M, Abdala, Edson, Reina Magalhães, Maira, Mularoni, Alessandra, Monaco, Francesco, Camera Pierrotti, Ligia, Pinheiro Freire, Maristela, Iyer, Ranganathan N, Mehta Steinke, Seema, Grazia Calvi, Elisa, Tumbarello, Mario, Falcone, Marco, Fernández-Ruiz, Mario, María Costa-Mateo, José, Rana, Meenakshi M, Mara Varejão Strabelli, Tania, Paul, Mical, Carmen Fariñas, María, Trindade Clemente, Wanessa, Roilides, Emmanuel, Muñoz, Patricia, Dewispelaere, Laurent, Loeches, Belén, Lowman, Warren, Hock Tan, Ban, Escudero-Sánchez, Rosa, Bodro, Marta, Antonio Grossi, Paolo, Soldani, Fabio, Gunseren, Filiz, Nestorova, Nina, Pascual, Álvaro, Martínez-Martínez, Lui, María Aguado, José, Rodríguez-Baño, Jesú, Torre-Cisneros, Julián, Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pérez-Nadales, Elena, Gutiérrez-Gutiérrez, Belén, Natera, Alejandra M, Abdala, Edson, Reina Magalhães, Maira, Mularoni, Alessandra, Monaco, Francesco, Camera Pierrotti, Ligia, Pinheiro Freire, Maristela, Iyer, Ranganathan N, Mehta Steinke, Seema, Grazia Calvi, Elisa, Tumbarello, Mario, Falcone, Marco, Fernández-Ruiz, Mario, María Costa-Mateo, José, Rana, Meenakshi M, Mara Varejão Strabelli, Tania, Paul, Mical, Carmen Fariñas, María, Trindade Clemente, Wanessa, Roilides, Emmanuel, Muñoz, Patricia, Dewispelaere, Laurent, Loeches, Belén, Lowman, Warren, Hock Tan, Ban, Escudero-Sánchez, Rosa, Bodro, Marta, Antonio Grossi, Paolo, Soldani, Fabio, Gunseren, Filiz, Nestorova, Nina, Pascual, Álvaro, Martínez-Martínez, Lui, María Aguado, José, Rodríguez-Baño, Jesú, Torre-Cisneros, Julián, and Tumbarello, Mario (ORCID:0000-0002-9519-8552)

Abstract

Treatment of carbapenemase-producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid organ transplant recipients with carbapenemase-producing Enterobacterales bloodstream infections. A multinational, retrospective (2004-2016) cohort study (INCREMENT-SOT, ClinicalTrials.gov NCT02852902) was performed. The main outcome variable was 30-day all-cause mortality. The INCREMENT-SOT-CPE score was developed using logistic regression. The global cohort included 216 patients. The final logistic regression model included the following variables: INCREMENT-CPE mortality score ≥8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between INCREMENT-CPE score ≥8 and CMV disease (minus 7 points). This score showed an area under the receiver operating characteristic curve of 0.82 (95% confidence interval [CI] 0.76-0.88) and classified patients into 3 strata: 0-7 (low mortality), 8-11 (high mortality), and 12-17 (very-high mortality). We performed a stratified analysis of the effect of monotherapy vs combination therapy among 165 patients who received appropriate therapy. Monotherapy was associated with higher mortality only in the very-high (adjusted hazard ratio [HR] 2.82, 95% CI 1.13-7.06, P = .03) and high (HR 9.93, 95% CI 2.08-47.40, P = .004) mortality risk strata. A score-based algorithm is provided for therapy guidance.

Published
2019

21. Inter-center agreement in the interpretation of oligoclonal bands.

Author

Mariotto, Sara, Ferraro, Diana, Soldani, Fabio, Alberti, Daniela, Bedin, Roberta, Sola, Patrizia, Gastaldi, Matteo, Franciotta, Diego, and Ferrari, Sergio

Subjects
CEREBROSPINAL fluid examination, IMMUNOGLOBULIN G, MEDICAL personnel, ISOELECTRIC focusing
Abstract

To the Editor, Oligoclonal immunoglobulin G (IgG) bands (OCBs), which are determined with electrophoretic techniques, are composed of clonal immunoglobulins produced by plasmablasts/plasma cells in the central nervous system (CNS) parenchyma and meningeal tertiary lymphoid follicles. Serum and CSF samples were analyzed with home-made agarose gel-based IEF technique (precast IsoGel Agarose IEF plates, pH 3-10 Lonza, Rockland, ME) with immunoblotting and staining for anti-human IgG [[2]], [[5]]. Results of IEF run analysis in 264 paired serum and CSF samples were independently evaluated by the three involved centers. [Extracted from the article]

Published
2021
Full Text
View/download PDF

22. Multidrug-resistant Combined Infections in a Liver Transplanted Patient: Case Report

Author

Carraro, Amedeo, Montin, Umberto, Violi, Paola, Soldani, Fabio, Mazzi, Romualdo, Merighi, Mara, Kanani, Faheem, Concia, Ercole, and Tedeschi, Umberto

Subjects
Time Factors, Coinfection, Liver Abscess, Enterobacteriaceae Infections, Liver Transplanted Patient, Enterobacter aerogenes, Microbial Sensitivity Tests, Anti-Bacterial Agents, Klebsiella Infections, Liver Transplantation, Klebsiella pneumoniae, Treatment Outcome, Drug Resistance, Multiple, Bacterial, Positron Emission Tomography Computed Tomography, Drainage, Humans, multidrug-resistant infections, Liver Transplanted Patient, Drug Therapy, Combination, Female, multidrug-resistant infections, Aged
Abstract

We report a case of successfully treated multiple liver abscesses in a liver-transplanted patient, sustained by combined multidrug-resistant infections. Two months after a liver transplant, a computed tomography scan revealed the presence of multiple abscesses in the liver graft. Blood cultures and abscessual liver fluid were both positive for acquired colistin- and carbapenem- resistant Klebsiella pneumoniae and an extended-spectrum of beta-lactamases-producing Enterobacter aerogenes. The treatment strategy consisted of different prolonged antimicrobial combinations and draining of the abscesses with complete recovery of the liver lesions.

Published
2016

27. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients

Author

Ciccosanti, Fabiola, primary, Corazzari, Marco, additional, Soldani, Fabio, additional, Matarrese, Paola, additional, Pagliarini, Vittoria, additional, Iadevaia, Valentina, additional, Tinari, Antonella, additional, Zaccarelli, Mauro, additional, Perfettini, Jean-Luc, additional, Malorni, Walter, additional, Kroemer, Guido, additional, Antinori, Andrea, additional, Fimia, Gian Maria, additional, and Piacentini, Mauro, additional

Published
2010
Full Text
View/download PDF

28. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir

Author

Trotta, Maria Paola, primary, Bonfigli, Sandro, additional, Ceccherini-Silberstein, Francesca, additional, Bellagamba, Rita, additional, D'Arrigo, Roberta, additional, Soldani, Fabio, additional, Zaccarelli, Mauro, additional, Concetta Bellocchi, Maria, additional, Lorenzini, Patrizia, additional, Marconi, Patrizia, additional, Boumis, Evangelo, additional, Forbici, Federica, additional, Comandini, Ubaldo Visco, additional, Tozzi, Valerio, additional, Narciso, Pasquale, additional, Federico Perno, Carlo, additional, and Antinori, Andrea, additional

Published
2006
Full Text
View/download PDF

29. Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting

Author

Puro, Vincenzo, primary, Cicalini, Stefania, additional, Carli, Gabriella De, additional, Soldani, Fabio, additional, Antunes, Francisco, additional, Balslev, Ulla, additional, Begovac, Josip, additional, Bernasconi, Enos, additional, Boaventura, José L., additional, Martí, Magda Campins, additional, Civljak, Rok, additional, Evans, Barry, additional, Francioli, Patrick, additional, Genasi, Fiona, additional, Larsen, Christine, additional, Lot, Florence, additional, Lunding, Suzanne, additional, Marcus, Ulrich, additional, Pereira, Alvaro A., additional, Thomas, Tania, additional, Schonwald, Slavko, additional, and Ippolito, Giuseppe, additional

Published
2003
Full Text
View/download PDF

30. Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy.

Author

Zaccarrelli, Mauro, Perno, Carlo Federico, Forbici, Federica, Soldani, Fabio, Bonfigli, Sandro, Gori, Caterina, Trotta, Maria Paola, Bellocchi, Maria Concetta, Liuzzi, Giuseppina, D'Arrigo, Roberta, De Longis, Patrizio, Boumis, Evangelo, Bellagamba, Rita, Tozzi, Valerio, Narcisco, Pasquale, and Antinori, Andrea

Subjects
AIDS patients, HIV-positive persons, VIRUS diseases, GENES
Abstract

Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4[sup+] lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

32. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients

Author

Walter Malorni, Marco Corazzari, Fabiola Ciccosanti, Mauro Piacentini, Fabio Soldani, Jean-Luc Perfettini, Vittoria Pagliarini, Paola Matarrese, Antonella Tinari, Andrea Antinori, Mauro Zaccarelli, Valentina Iadevaia, Guido Kroemer, Gian Maria Fimia, Ciccosanti, Fabiola, Corazzari, Marco, Soldani, Fabio, Matarrese, Paola, Pagliarini, Vittoria, Iadevaia, Valentina, Tinari, Antonella, Zaccarelli, Mauro, Perfettini, Jean Luc, Malorni, Walter, Kroemer, Guido, Antinori, Andrea, Fimia, Gian Maria, and Piacentini, Mauro

Subjects
Electrophoresis, Proteomics, HAART, Settore BIO/06, Anti-HIV Agents, Antiretroviral Therapy, Down-Regulation, HIV Infections, Biology, HIV, mitocondri, Downregulation and upregulation, Antiretroviral Therapy, Highly Active, Stavudine, Electrophoresis, Gel, Two-Dimensional, Repressor Proteins, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Humans, Mitochondria, Reverse Transcriptase Inhibitors, HIV-1, Zidovudine, Prohibitins, Matrix-Assisted Laser Desorption-Ionization, Hiv infected patients, Highly Active, Pharmacology (medical), HIV Infection, Prohibitin, Pharmacology, Settore BIO/11 - BIOLOGIA MOLECOLARE, Gel, Spectrometry, virus diseases, Anti-HIV Agent, Proteomic, Mass, Repressor Protein, Antiretroviral therapy, Reverse Transcriptase Inhibitor, Infectious Diseases, Two-Dimensional, Immunology, Human
Abstract

Background Highly active antiretroviral therapy (HAART) has largely reduced the occurrence of AIDS-related diseases and death in HIV-infected patients. However, HAART produces serious side effects mainly attributed to mito-chondrial toxicity. Methods To elucidate the molecular basis of HAART-related dysfunctions, we analysed the mitochondrial proteome of peripheral blood mononuclear cells from HIV-infected patients using two-dimensional gel electrophoresis and MALDI-TOF/TOF mass spectrometry. Proteomic analysis was performed on HIV patients who were either treatment- naive or under HAART therapy including zidovudine or stavudine as nucleoside reverse transcriptase inhibitors (NRTIs). Results As compared to healthy donors, HAART-treated HIV-infected patients exhibited decreased levels of mitochondrial enzymes associated with energy production as well as mitochondrial chaperones. Moreover, significant alterations in the mitochondria–cytoskeleton network were observed. Notably, most of these changes were already detectable in untreated HIV carriers and persisted or worsened after HAART, indicating that relevant mitochondrial alterations were initially caused by HIV infection. Finally, in vitro experiments aimed at validating the proteomic results showed that down-regulation of the mitochondrial chaperone prohibitin is a causative event in NRTI-induced mitochondrial damage. Conclusions Our results indicate a major role of HIV infection in the mitochondrial toxicity of HAART-treated patients and identify novel candidate markers for assessing the risk of HIV- and HAART-related pathologies.

Published
2010

33. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients.

Author

Gutiérrez-Gutiérrez B, Pérez-Nadales E, Pérez-Galera S, Fernández-Ruiz M, Carratalà J, Oriol I, Cordero E, Lepe JA, Tan BH, Corbella L, Paul M, Natera AM, David MD, Montejo M, Iyer RN, Pierrotti LC, Merino E, Steinke SM, Rana MM, Muñoz P, Mularoni A, van Delden C, Grossi PA, Seminari EM, Gunseren F, Lease ED, Roilides E, Fortún J, Arslan H, Coussement J, Tufan ZK, Pilmis B, Rizzi M, Loeches B, Eriksson BM, Abdala E, Soldani F, Lowman W, Clemente WT, Bodro M, Fariñas MC, Kazak E, Martínez-Martínez L, Aguado JM, Torre-Cisneros J, Pascual Á, and Rodríguez-Baño J

Subjects
Anti-Bacterial Agents therapeutic use, Cohort Studies, Ertapenem, Humans, Propensity Score, Retrospective Studies, beta-Lactamases, Bacteremia drug therapy, Kidney Transplantation, Urinary Tract Infections drug therapy
Abstract

There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P  = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P  = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.

Published
2021
Full Text
View/download PDF

34. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).

Author

Pierrotti LC, Pérez-Nadales E, Fernández-Ruiz M, Gutiérrez-Gutiérrez B, Tan BH, Carratalà J, Oriol I, Paul M, Cohen-Sinai N, López-Medrano F, San-Juan R, Montejo M, Freire MP, Cordero E, David MD, Merino E, Mehta Steinke S, Grossi PA, Cano Á, Seminari EM, Valerio M, Gunseren F, Rana M, Mularoni A, Martín-Dávila P, van Delden C, Hamiyet Demirkaya M, Koçak Tufan Z, Loeches B, Iyer RN, Soldani F, Eriksson BM, Pilmis B, Rizzi M, Coussement J, Clemente WT, Roilides E, Pascual Á, Martínez-Martínez L, Rodríguez-Baño J, Torre-Cisneros J, and Aguado JM

Subjects
Anti-Bacterial Agents therapeutic use, Carbapenems, Enterobacteriaceae Infections drug therapy, Humans, Lactams, Retrospective Studies, beta-Lactamase Inhibitors therapeutic use, beta-Lactamases, Bacteremia drug therapy, Kidney Transplantation, Urinary Tract Infections drug therapy
Abstract

Background: Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear., Methods: We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively., Results: Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count ≤500 cells/μL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes., Conclusions: Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902)., (© 2020 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

35. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia.

Author

Pérez-Nadales E, Gutiérrez-Gutiérrez B, Natera AM, Abdala E, Reina Magalhães M, Mularoni A, Monaco F, Camera Pierrotti L, Pinheiro Freire M, Iyer RN, Mehta Steinke S, Grazia Calvi E, Tumbarello M, Falcone M, Fernández-Ruiz M, María Costa-Mateo J, Rana MM, Mara Varejão Strabelli T, Paul M, Carmen Fariñas M, Clemente WT, Roilides E, Muñoz P, Dewispelaere L, Loeches B, Lowman W, Tan BH, Escudero-Sánchez R, Bodro M, Antonio Grossi P, Soldani F, Gunseren F, Nestorova N, Pascual Á, Martínez-Martínez L, Aguado JM, Rodríguez-Baño J, and Torre-Cisneros J

Abstract

Treatment of carbapenemase-producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid organ transplant recipients with carbapenemase-producing Enterobacterales bloodstream infections. A multinational, retrospective (2004-2016) cohort study (INCREMENT-SOT, ClinicalTrials.gov NCT02852902) was performed. The main outcome variable was 30-day all-cause mortality. The INCREMENT-SOT-CPE score was developed using logistic regression. The global cohort included 216 patients. The final logistic regression model included the following variables: INCREMENT-CPE mortality score ≥8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between INCREMENT-CPE score ≥8 and CMV disease (minus 7 points). This score showed an area under the receiver operating characteristic curve of 0.82 (95% confidence interval [CI] 0.76-0.88) and classified patients into 3 strata: 0-7 (low mortality), 8-11 (high mortality), and 12-17 (very-high mortality). We performed a stratified analysis of the effect of monotherapy vs combination therapy among 165 patients who received appropriate therapy. Monotherapy was associated with higher mortality only in the very-high (adjusted hazard ratio [HR] 2.82, 95% CI 1.13-7.06, P = .03) and high (HR 9.93, 95% CI 2.08-47.40, P = .004) mortality risk strata. A score-based algorithm is provided for therapy guidance., (© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.)

Published
2019
Full Text
View/download PDF

36. [Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].

Author

Gottardi M, Lanzafame M, Lattuada E, Soldani F, Boccafoglio F, and Concia E

Subjects
Adenine analogs & derivatives, Adult, Alkynes, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Benzoxazines pharmacology, Benzoxazines therapeutic use, CD4 Lymphocyte Count, Cyclopropanes, Deoxycytidine analogs & derivatives, Dideoxynucleosides, Drug Therapy, Combination, Emtricitabine, Female, HIV Infections blood, HIV-1, Humans, Hyperinsulinism chemically induced, Hyperlipidemias chemically induced, Lamivudine, Male, Middle Aged, Mutation, Organophosphonates, Prospective Studies, Tenofovir, Thymidine metabolism, Treatment Outcome, Young Adult, Anti-HIV Agents therapeutic use, HIV Infections drug therapy
Abstract

To assess the potency, efficacy and toxicity of abacavir/lamivudine (ABC/3TC) versus tenfovir/emcitrabine (TDF/FTC) with efavirenz (EFV) in naive patients with HIV infection a prospective observational study was carried out to evaluate immunovirological parameters every three months and metabolic parameters every six months. In all, 21 patients were enrolled (10 on ABC/3TC and 11 on TDF/FTC). Fisher's test revealed no statistically significant difference between the two arms in terms of immunological recovery and control of viral replication. For metabolic parameters at week 48 no statistically significant differences were noted between the two arms. The two ABC/3TC and TDF/FTC backbones showed the same potency; ABC had a more negative impact on metabolic parameters without statistical power.

Published
2009

37. Optimal fosamprenavir regimen to prevent lipid abnormalities.

Author

Lattuada E, Lanzafame M, Grosso C, Soldani F, Corsini F, Storato S, and Vento S

Subjects
Adult, Drug Therapy, Combination, Female, Furans, HIV Protease Inhibitors administration & dosage, Humans, Hyperlipidemias chemically induced, Male, Middle Aged, Ritonavir administration & dosage, Triglycerides blood, Anti-HIV Agents administration & dosage, Carbamates administration & dosage, HIV Seropositivity blood, HIV Seropositivity drug therapy, Organophosphates administration & dosage, Sulfonamides administration & dosage
Abstract

We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naive monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir. (www.actabiomedica.it)

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results